Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma

BACKGROUND: Non-Hodgkin’s lymphomas are the eighth-most prevalent malignancy in females and the eleventh in males. No research has been conducted comparing dexamethasone, cytarabine cisplatin (DHAP) vs. ifosfamide, carboplatin, etoposide (ICE) as salvage chemotherapy regimens for relapsed or refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Devi, Kanta, Soomar, Salman Muhammad, Shaikh, Muhammad Usman, Ali, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473291/
https://www.ncbi.nlm.nih.gov/pubmed/37663724
http://dx.doi.org/10.1097/MS9.0000000000000956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473291/
https://www.ncbi.nlm.nih.gov/pubmed/37663724
http://dx.doi.org/10.1097/MS9.0000000000000956

Ejemplares similares